Close
What would you like to look for?
Site search
Search filters

Memo Therapeutics AG Increases Series C Financing to CHF 45m

15 May 2024

Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised CHF 20m as part of an extension of its series C financing round.

Alex Frei becomes a shareholder and board member at DuBois et fils

17 January 2024

Alex Frei, footballer, coach and record goalscorer for the Swiss national team, has acquired a stake in the watch brand DuBois et fils, which has been based in Basel since 2012.

SWIMRUN expands into the US market with investment in Ödyssey Series

30 November 2023

SWIMRUN AG, the organizer of major swimrun events, has acquired a majority stake in Swimrun USA Inc., which owns all rights to the Ödyssey Swimrun Series in the United States. Following the transaction, SWIMRUN will be the market...

Sale of T3 Pharmaceuticals AG to Boehringer Ingelheim

23 November 2023

T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has been acquired by Boehringer Ingelheim, a leading family-owned, research-driven biopharmaceutical company based in Ingelheim, Germany...

Nouscom Raises EUR 67.5m in Oversubscribed Series C Financing Round

14 November 2023

Nouscom AG, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate of re-nowned international healthcare investors.

Follow-On Offering of Oculis Holding AG

8 June 2023

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share, for gross proceeds of USD 40.25m, before deducting underwriting discounts and commissions and offering expenses.

Medartis increases stake in KeriMedical

20 March 2023

Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private founders of KeriMedical, a Geneva-based private company specializing in the development and manufacture of implants for hand and wrist surgery, to acquire an additional 18% stake for a purchase price of approximately CHF 18m.

Oculis to list on NASDAQ

7 March 2023

Oculis Holding AG ("Oculis") a global biopharmaceutical company purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”).

Resistell AG closes series B first tranche of CHF 8.5m

23 December 2022

Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5m from new and existing investors.

Oculis SA and European Biotech Acquisition Corp announce business combination

26 October 2022

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (NASDAQ: EBAC), a special purpose acquisition company (SPAC), announced they have entered into a definitive business combination agreement.